Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: A method and system for treating brain disorders comprises detecting activity of a first target area of the brain via a first implanted sensor and determining the presence of target brain activity by analyzing the detected brain activity in combination with treating the user based upon the determined presence of target brain activity by supplying a first therapeutic agent to the first target area via a first implanted fluid delivery member including at least one distal opening adjacent to the first target area. In addition, the system may be used as well for testing the effectiveness of drugs.

Abstract: A device comprises a head mounting arrangement sized and shaped to be worn on a user's head and a plurality of electrodes disposed on the arrangement so that, when the arrangement is worn on the user's head, the electrodes contact target portions of a scalp to detect electrical activity of a brain of the user in combination with an image capture device disposed on the arrangement so that, when the arrangement is worn on the user's head, a field of view of the image capture device includes a portion of an anatomy of the user and a processing unit generating EEG data from the electrical activity, wherein, when the EEG data is indicative of an epileptic event, the processing unit activates the image capture device to capture video data of the user and may store the EEG and/or the video data with transmission of warning signals to one or more remote displaying and/or computing arrangements.

Abstract: A device comprises a head mounting arrangement sized and shaped to be worn on a user's head and a plurality of electrodes disposed on the arrangement so that, when the arrangement is worn on the user's head, the electrodes contact target portions of a scalp to detect electrical activity of a brain of the user in combination with an image capture device disposed on the arrangement so that, when the arrangement is worn on the user's head, a field of view of the image capture device includes a portion of an anatomy of the user and a processing unit generating EEG data from the electrical activity, wherein, when the EEG data is indicative of an epileptic event, the processing unit activates the image capture device to capture video data of the user and may store the EEG and/or the video data with transmission of warning signals to one or more remote displaying and/or computing arrangements.

Abstract: A device comprises a head mounting arrangement sized and shaped to be worn on a user's head and a plurality of electrodes disposed on the arrangement so that, when the arrangement is worn on the user's head, the electrodes contact target portions of a scalp to detect electrical activity of a brain of the user in combination with an image capture device disposed on the arrangement so that, when the arrangement is worn on the user's head, a field of view of the image capture device includes a portion of an anatomy of the user and a processing unit generating EEG data from the electrical activity, wherein, when the EEG data is indicative of an epileptic event, the processing unit activates the image capture device to capture video data of the user and may store the EEG and/or the video data with transmission of warning signals to one or more remote displaying and/or computing arrangements.

Abstract: A method and system for treating brain disorders comprises detecting activity of a first target area of the brain via a first implanted sensor and determining the presence of target brain activity by analyzing the detected brain activity in combination with treating the user based upon the determined presence of target brain activity by supplying a first therapeutic agent to the first target area via a first implanted fluid delivery member including at least one distal opening adjacent to the first target area. In addition, the system may be used as well for testing the effectiveness of drugs.